Toronto, Ontario – TheNewswire - 29 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced financial results for the 2025 fiscal year ended July 31, 2025. OverviewThe Company reported a net loss and total comprehensive loss of $5,205,000 for the year ended July 31, 2025, (July 31, 2024:$9,264,000) and a loss of $0.09 per common s ...